Priorities for public health preparedness for psychedelics: education, workforce readiness, and strategic information needs in a rapidly changing landscape
R. Cameron Wolf, Rick Lambert, Sara Shoar, Joshua S. Hunt, Ingrid Donato, Neeraj Gandotra
Frontiers in Public Health August 6, 2026 DOI: 10.3389/fpubh.2026.1900601 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | Argues that public health preparedness for psychedelics should focus on three priorities: education and prevention of adverse events, behavioral health workforce development, and strategic information and data analysis, to support safety and responsible evidence development. |
Abstract
Use of psychedelic substances is increasing across unregulated, state-regulated, research, ceremonial/religious, and medical settings in the United States. Concurrently, a growing body of clinical research signals the potential for therapeutic applications for specific psychedelics in the treatment of depression, post-traumatic stress disorder, substance use disorders, and other health conditions. This evolving landscape presents both promise and complexity. From a public health perspective, a structured public health preparedness approach is needed to prioritize safety, workforce readiness, and data infrastructure in a manner that promotes individual and collective well-being while supporting responsible evidence development. This commentary proposes priorities for public health preparedness for psychedelics: (1) education and prevention of adverse events; (2) behavioral health workforce development; and (3) strategic information and data analysis. Educational efforts should emphasize clear risk communication, substance-specific messaging, prevention of adverse events, and practical guidance to support policy decision-making. Workforce considerations include defining core competencies, clarifying ethical boundaries and informed consent, establishing training and technical assistance infrastructure, strengthening capacity across the behavioral health workforce, and preparing providers to respond to patients using psychedelics outside regulated systems. Strategic information priorities include strengthening data systems and improving coordination and harmonization of epidemiologic monitoring related to patterns of use, adverse events, treatment-seeking behaviors, and the implications of evolving policy environments. As psychedelics enter mainstream discourse, public health institutions must adopt a balanced approach that considers both benefits and risks. A proactive, health-promoting, and data-driven framework can help ensure that policies and practices are grounded in safety and core public health principles.
Citations in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
and 14 more in the library